Getting started
New to Norwegian market access?
Norway has one of the most structured — and most navigable — market access systems in Europe. This guide walks you through the five agencies you need to know, the two reimbursement routes, how the Nye metoder process works, and which resources to bookmark first.
How the system is structured
Norwegian market access operates across two parallel tracks depending on the care setting:
Medicines reimbursed via blåresept (blue prescription) and administered through pharmacies. Managed by DMP (pricing/listing) and HELFO (reimbursement payments).
Medicines funded via H-resept directly by regional health authorities. Procurement handled through national LIS tenders run by Sykehusinnkjøp. Requires Nye metoder assessment.
Beslutningsforum makes the final yes/no decision for specialist care medicines. It meets monthly and publishes all decisions publicly — making Norway unusually transparent.
How the system works — at a glance
Click any step to learn more. Use the route buttons to highlight the blåresept or H-resept pathway.
The 5 agencies you need to know
Norwegian Medicines Agency. Conducts HTA assessments for blåresept listings, sets maximum prices, and regulates medicines. Your first port of call for submission requirements and PE guidelines.
dmp.no ↗The national system for managed introduction of new methods in specialist care. Coordinates the HTA process from horizon scanning through to Beslutningsforum's funding decision.
nyemetoder.no ↗Administers reimbursement payments for blåresept medicines. Also handles individual applications (§3a) for patients needing medicines outside the standard listing.
helfo.no ↗Runs national LIS tenders for hospital medicines on behalf of all four regional health authorities. LIS contract prices are confidential but tender notices are published on Doffin.
sykehusinnkjop.no ↗Norwegian Institute of Public Health. Produces independent health economic analyses and maintains key registers including the Norwegian Patient Registry (NPR).
fhi.no ↗The two reimbursement routes
- For chronic conditions treated in primary/outpatient care
- §2 = automatic (pliktmessig) for listed indications
- §3a = individual application for unlisted cases
- DMP assesses and lists; HELFO pays
- Prices set via DMP maximum price system
- Trinnpris applies when generics enter
- For specialist care — oncology, biologics, rare diseases
- Funded directly by regional health authorities (RHF)
- Requires Nye metoder HTA assessment
- Beslutningsforum makes final funding decision
- Prices negotiated via LIS tender (confidential)
- No patient co-payment
Which route applies to your product? If it will be administered in a hospital or by a specialist, it almost certainly goes via H-resept and Nye metoder. If it treats a chronic condition managed in primary care (diabetes, asthma, hypertension), it likely goes via blåresept. Some products have both routes — a hospital-initiated medicine that continues in primary care.
How Nye metoder works
Nye metoder is the managed introduction system for specialist care. The process has four stages:
Early notification when a method approaches EMA approval. Companies or clinicians submit a varsel to trigger the process early. The earlier the better.
Company submits an STA dossier following DMP's guidelines. DMP conducts an independent health economic assessment. Timeline is typically 6–12 months.
Sykehusinnkjøp negotiates a confidential price with the company before Beslutningsforum meets. The negotiated price is a condition of a positive decision.
The four regional health authority CEOs meet monthly and vote yes/no on funding. Decisions are published publicly within days. A yes means nationwide access.
Your first 10 resources to bookmark
These are the pages market access teams open most often. Start here.
Want the full directory? The hub has 56 verified links across all categories — DMP, Nye metoder, HELFO, Sykehusinnkjøp, Beslutningsforum, clinical guidelines, epidemiology data, legal references and more. Browse all resources →
Key terms to know
Norwegian market access has its own vocabulary. The most important terms to know before your first submission:
Metodevurdering — health technology assessment. The formal evaluation of clinical and economic value.
Blåresept — blue prescription. The outpatient reimbursement scheme, split into §2 (automatic) and §3a (individual application).
H-resept — hospital prescription. Medicines funded by regional health authorities for specialist care.
LIS — hospital medicines procurement tender. Run nationally by Sykehusinnkjøp.
Trinnpris — step price. Mandatory price reductions when generics enter the market.
QALY — quality-adjusted life year. The primary outcome measure used in Norwegian HEMs, with severity-adjusted WTP thresholds.